Hangzhou Richerpharm Technology Co.,Ltd.
Hangzhou Richerpharm Technology Co.,Limited engaged in the development, production and marketing of pharmaceutical products, food ingredients, vitamins, intermediates and chemicals.
Richerharm headquarters in Hangzhou, China, with 3 production bases in Shandong, Zhejiang and Hebei separately, which have many years of experience in the production of APIs, vitamins and chemical products. These facilities have been certified GMP, ISO, FAMI-QS, KOSHER, HALAL, etc. We have complete control over our product development, design, and manufacturing processes, thanks to our advanced equipment, methods, and inspection facilities.
With key competencies in pharmaceuticals and food health, Richer Pharma has established extensive business networks around the world. We have Strategic Marketing Partners in Mumbai and Dubai respectively. We are ready to provide you with our best products and services.
Shanghai Jinhe Biopharmaceutical Co., Ltd.: 2002 Founded in 2003, based on the scientific research results of Fudan University, it undertakes the international paclitaxel API processing business. It has successfully developed products such as paclitaxel, docetaxel, irinotecan, etoposide, etc., and has developed from natural anti-tumor drugs to plant-derived anti-tumor drug raw materials. Later, it developed products such as cabazitaxel and palonosetron hydrochloride. In 2012, it became the anti-tumor API production base of Shanghai Pharmaceutical Group.
Jiangsu Senxuan Pharmaceutical Co., Ltd.: It is mainly engaged in the research and development, production and sales of chemical APIs, pharmaceutical intermediates and oxygen-containing heterocyclic chemical intermediates. The APIs cover anti-tumor, antipyretic, analgesic, anti-inflammatory, anti-epileptic, etc., and have 16 API varieties such as phenobarbital, fluorouracil, and phenylbutazone.
Hisun Pharmaceutical: A long-established leading enterprise in the field of domestic APIs, it has independently developed drugs such as HS387 tablets for the treatment of advanced solid tumors, and its products cover a variety of anti-tumor APIs.
Taihua Natural Biopharmaceutical Co., Ltd.: Founded in 1993, headquartered in Luonan County, Shangluo City, Shaanxi Province, with homoharringtonine, paclitaxel and other anti-tumor APIs as core products, the products are sold to countries and regions such as the European Union and Israel.
Shanghai Chuangnuo Pharmaceutical Co., Ltd.: Founded in 2005, it focuses on the research, development, production and sales of anti-tumor drug raw materials and preparations. It has an anti-tumor drug industrialization platform and the Shanghai Anti-tumor Drug Chemical Drug Engineering Technology Research Center, and has complete independent cytotoxic and non-cytotoxic GMP production lines.
Sinopharm Sichuan Kang Pharmaceutical Co., Ltd.: It is a subsidiary of Shanghai Modern Pharmaceutical Co., Ltd. under Sinopharm Group. It is a national high-tech enterprise and a "specialized, refined and innovative" small and medium-sized enterprise in Sichuan Province. It is committed to the research, development, production and operation of biological immunosuppressants and anti-tumor therapeutic drugs. The technological advancement of products such as tacrolimus and granisetron hydrochloride is at the forefront of the country.